Treats myxedema coma/precoma. ANDA 76923, held by Xgen Pharms. Liothyronine Sodium.
As of Nov 16, 2026, ANDA 76923 (Liothyronine Sodium), held by Xgen Pharms, was first approved by FDA on Aug 17, 2005, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Liothyronine sodium injection (T 3 ) is indicated in the treatment of myxedema coma/precoma. Liothyronine sodium injection (T 3 ) can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2005 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Liothyronine SodiumEQ 0.01MG BASE/ML · injectable;injection | Liothyronine Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters